Prothena Corporation PLC (NASDAQ: PRTA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
This table compares Prothena Corporation PLC and PTC Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Prothena Corporation PLC||-527.56%||-33.20%||-27.66%|
Prothena Corporation PLC has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.
Institutional and Insider Ownership
81.3% of PTC Therapeutics shares are owned by institutional investors. 3.1% of Prothena Corporation PLC shares are owned by company insiders. Comparatively, 8.1% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Prothena Corporation PLC and PTC Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Prothena Corporation PLC||0||0||12||0||3.00|
Prothena Corporation PLC currently has a consensus price target of $79.73, suggesting a potential upside of 29.76%. PTC Therapeutics has a consensus price target of $16.38, suggesting a potential downside of 10.91%. Given Prothena Corporation PLC’s stronger consensus rating and higher probable upside, research analysts plainly believe Prothena Corporation PLC is more favorable than PTC Therapeutics.
Valuation and Earnings
This table compares Prothena Corporation PLC and PTC Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Prothena Corporation PLC||$27.53 million||85.42||-$135.60 million||($4.12)||-14.91|
|PTC Therapeutics||$122.69 million||6.19||-$90.43 million||($3.10)||-5.93|
PTC Therapeutics has higher revenue and earnings than Prothena Corporation PLC. Prothena Corporation PLC is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Prothena Corporation PLC beats PTC Therapeutics on 7 of the 13 factors compared between the two stocks.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
What are top analysts saying about Prothena Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prothena Corporation PLC and related companies.